{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:13:11Z","timestamp":1788545591511,"version":"build-2803163510"},"reference-count":20,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Background: This cross-sectional study compared immunoassay urine drug screening with LC\u2013MS\/MS confirmation in individuals with substance use disorder undergoing probation monitoring, focusing on samples with results close to assay cutoff values. Methods: The study was conducted between January and March 2026 in \u015eanl\u0131urfa, T\u00fcrkiye, and included 110 individuals followed at an Addiction Treatment Center (AMATEM). Urine samples with at least one analyte result within \u00b120% of the cutoff value were analyzed. Immunoassay screening was performed using a Beckman Coulter AU480 analyzer, whereas confirmation was performed by LC\u2013MS\/MS using a SCIEX Triple Quad 5500+ system. Agreement was evaluated using Cohen\u2019s kappa and McNemar\u2019s test, while diagnostic performance was assessed using 2 \u00d7 2 contingency tables. Results: Agreement varied substantially among analyte groups. Buprenorphine showed the highest agreement (\u03ba = 0.47), followed by amphetamines (\u03ba = 0.33), whereas opioids showed very low agreement (\u03ba = 0.081). Benzodiazepines, cocaine, and cannabinoids showed no meaningful agreement; however, benzodiazepine and cocaine findings were limited by very low numbers of positive cases. Immunoassay screening produced notable false-positive results for amphetamines and opioids and false-negative results for cannabinoids and opioids. Conclusions: Immunoassay performance was analyte-dependent and appeared limited in samples with results close to cutoff values. LC\u2013MS\/MS confirmation remains important for reliable toxicological interpretation in probation monitoring settings.<\/jats:p>","DOI":"10.3390\/metabo16090651","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:25:56Z","timestamp":1788542756000},"page":"651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Immunoassay Results near Cutoff Values with LC-MS\/MS in Individuals with Substance Use Disorder Under Probation"],"prefix":"10.3390","volume":"16","author":[{"given":"Ugur Fahri","family":"Yurekli","sequence":"first","affiliation":[{"name":"Department of Biochemistry, University of Health Sciences, \u015eanl\u0131urfa Mehmet Akif \u0130nan Training and Research Hospital, \u015eanl\u0131urfa 63300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Ozlem Orer","family":"Beginoglu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, \u015eanl\u0131urfa Mehmet Akif \u0130nan Training and Research Hospital, \u015eanl\u0131urfa 63300, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: Practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","first-page":"635","article-title":"Urine drug screening: A valuable office procedure","volume":"81","author":"Standridge","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.acc.2022.08.001","article-title":"Drug testing in the era of new psychoactive substances","volume":"111","author":"Gerona","year":"2022","journal-title":"Adv. Clin. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/jalm\/jfae169","article-title":"Evaluation of Immunoassay Performance for the Detection of Opioids in Urine","volume":"10","author":"Walsh","year":"2025","journal-title":"J. Appl. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17425255.2023.2252324","article-title":"Current state-of-the-art approaches for mass spectrometry in clinical toxicology: An overview","volume":"19","author":"Peters","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.2174\/1381612828666220831103224","article-title":"Determination of Traditional and Designer Benzodiazepines in Urine through LC-MS\/MS","volume":"28","author":"Rossi","year":"2022","journal-title":"Curr. Pharm. Des."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jat\/bkab104","article-title":"Comparing ELISA and LC-MS-MS: A Simple, Targeted Postmortem Blood Screen","volume":"46","author":"Swanson","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jat\/bkae077","article-title":"Multi-class analysis of 57 drugs quantitatively in blood and qualitatively in urine by LC-MS-MS to complement comprehensive DFC, DUID, and postmortem testing","volume":"49","author":"Rodda","year":"2025","journal-title":"J. Anal. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11419-021-00600-y","article-title":"Determination of new psychoactive substances and other drugs in postmortem blood and urine by UHPLC-MS\/MS: Method validation and analysis of forensic samples","volume":"40","author":"Caldas","year":"2022","journal-title":"Forensic Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jmsacl.2021.12.008","article-title":"Development of a high-throughput differential mobility separation-tandem mass spectrometry (DMS-MS\/MS) method for clinical urine drug testing","volume":"23","author":"Hooshfar","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"124772","DOI":"10.1016\/j.jchromb.2025.124772","article-title":"Development and validation of a LC-MS\/MS method for the detection of 38 benzodiazepines and 2 Z-drugs in blood","volume":"1266","author":"Liu","year":"2025","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110884","DOI":"10.1016\/j.forsciint.2021.110884","article-title":"Simultaneous LC-MS\/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine","volume":"325","author":"Fan","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jat\/bkab075","article-title":"A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS","volume":"46","author":"Farley","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1515\/cclm-2021-0010","article-title":"Interpretable machine learning model to detect chemically adulterated urine samples analyzed by high resolution mass spectrometry","volume":"59","author":"Streun","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/15321819.2023.2189451","article-title":"Optimization of biochip assay for illegal substances on drug abusers\u2019 whole blood: Randox Evidence vs LC-MS\/MS","volume":"44","author":"Yucel","year":"2023","journal-title":"J. Immunoass. Immunochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jat\/25.8.670","article-title":"Performance of five non-instrumented urine drug-testing devices with challenging near-cutoff specimens","volume":"25","author":"Kadehjian","year":"2001","journal-title":"J. Anal. Toxicol."},{"key":"ref_17","first-page":"9","article-title":"Correlation of Drug-Testing Results\u2014Immunoassay versus Gas Chromatography-Mass Spectrometry","volume":"18","author":"Huang","year":"2006","journal-title":"Forensic Sci. Rev."},{"key":"ref_18","first-page":"38","article-title":"A Practical Guide to Urine Drug Monitoring","volume":"35","author":"Raouf","year":"2018","journal-title":"Fed. Pract."},{"key":"ref_19","first-page":"112","article-title":"Urine drug screening: A guide to monitoring Tx with controlled substances","volume":"70","author":"Hayes","year":"2021","journal-title":"J. Fam. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rossi, B., Freni, F., Vignali, C., Stramesi, C., Collo, G., Carelli, C., Moretti, M., Galatone, D., and Morini, L. (2021). Comparison of Two Immunoassay Screening Methods and a LC-MS\/MS in Detecting Traditional and Designer Benzodiazepines in Urine. Molecules, 27.","DOI":"10.3390\/molecules27010112"}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/9\/651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:39:51Z","timestamp":1788543591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/9\/651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["metabo16090651"],"URL":"https:\/\/doi.org\/10.3390\/metabo16090651","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]}}}